Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas

NCT00589381 is registered in ClinicalTrials.gov with National Institutes of Health Clinical Center (CC) as lead sponsor.

NCT NCT00589381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00589381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb™ (LXS) Oral Powder (4-HPR/LXS Oral Powder) (4-HPR) in Adults With Solid Tumors and Lymphomas
Lead sponsor
National Institutes of Health Clinical Center (CC)
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2007
Completion date
March 31, 2011
Enrollment
30 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, unspecified adult solid tumor, protocol specific